Allele | madcow | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mutation Type | missense | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Chromosome | 8 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Coordinate | 11,576,034 bp (GRCm39) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Base Change | A ⇒ T (forward strand) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Gene | Cars2 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Gene Name | cysteinyl-tRNA synthetase 2, mitochondrial | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Synonym(s) | 2410044A07Rik, 2310051N18Rik, D530030H10Rik | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Chromosomal Location | 11,564,017-11,600,781 bp (-) (GRCm39) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
MGI Phenotype |
FUNCTION: [Summary is not available for the mouse gene. This summary is for the human ortholog.] This gene encodes a putative member of the class I family of aminoacyl-tRNA synthetases. These enzymes play a critical role in protein biosynthesis by charging tRNAs with their cognate amino acids. This protein is encoded by the nuclear genome but is likely to be imported to the mitochondrion where it is thought to catalyze the ligation of cysteine to tRNA molecules. A splice-site mutation in this gene has been associated with a novel progressive myoclonic epilepsy disease with similar symptoms to MERRF syndrome. [provided by RefSeq, Mar 2015] PHENOTYPE: Mice homozygous for an ENU-induced allele develop induced hyperactivity followed by head bobbing and tremors. [provided by MGI curators] |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accession Number | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Mapped | Yes | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Amino Acid Change | Serine changed to Threonine | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Institutional Source | Beutler Lab | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Gene Model | not available | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
AlphaFold | no structure available at present | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SMART Domains |
Protein: ENSMUSP00000046453 Gene: ENSMUSG00000056228 AA Change: S305T
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Predicted Effect | probably damaging
PolyPhen 2 Score 1.000 (Sensitivity: 0.00; Specificity: 1.00) |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Predicted Effect | probably benign | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Predicted Effect | probably benign | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Meta Mutation Damage Score | Not available | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Is this an essential gene? | Probably essential (E-score: 0.956) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Phenotypic Category | Autosomal Recessive | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Candidate Explorer Status | loading ... | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Single pedigree Linkage Analysis Data |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Penetrance | 100% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Alleles Listed at MGI | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Lab Alleles |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Mode of Inheritance | Autosomal Recessive | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Local Stock | Live Mice, Sperm, gDNA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
MMRRC Submission | 034369-UNC | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Last Updated | 2019-04-18 11:53 AM by Bruce Beutler | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Record Created | unknown | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Record Posted | 2011-01-19 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Phenotypic Description | Madcow was derived from the Stamper stock, a pedigree that also gave rise to a coat color phenotype (stamper-coat) ascribed to Hps6, and a developmental phenotype (zigzag) ascribed to Lfng. Homozygous madcow mice develop a neurological phenotype with age, appearing in females by 4-5 months and in males by 8 months. Initially mice display hyperactivity, particularly when mildly stimulated by handling or transfer to a new cage environment (see video). After several months head-bobbing and tremor are also evident. No other defects are apparent in these animals, and madcow mice have a normal life-span and are able to breed.
In order to quantify the madcow behavioral defect, both horizontal and vertical activity of both wild-type and mutant animals were measured following transfer to a new cage environment (Figure 1). During the first 5 minutes of observation post-transfer, both madcow males and females displayed significantly increased horizontal activity starting at the age of 5 months (Figure 1A). The behavioral difference between wild type and mutant animals increased with age, peaking at 9 months. The difference in horizontal activity level between the two groups tapered off over a 2 hour period, but remained significant in mice that were 9 or 10 months of age (Figure 1B). In general, homozygous madcow mice displayed no differences in vertical activity (rearing, jumping) relative to wild-type animals (Figure 1C). Histological analysis of the brain, using hematoxylin and eosin staining in 9 month-old homozygous madcow mice, revealed no abnormalities.
Because hyperactivity can be caused by hearing defects, the auditory threshold were characterized by measuring the auditory brainstem response (ABR). Click stimuli were applied to the same groups of mice of both sexes at 2 and 6 months old starting with 90 dB and then decreasing the intensity. Auditory thresholds in both wild type and madcow mice were at about 40-50 dB with no significant differences between the two groups at either time point (Figure 2A). Also assessed were the auditory threshold for single tones at frequencies between 6 and 32 kHz, and the functionality of the mechanosensitive outer hair cells by measuring the distortion product otoacoustic emission (DPOAE). Again, no differences were found between madcow and wild type animals using these tests (Figure 2B,C), suggesting that madcow animals do not have a hearing defect. Madcow animals display no immunological phenotypes as assayed by several immunological screens (TLR Signaling Screen; Ex Vivo Macrophage Screen for Control of Viral Infection; MCMV Susceptibility and Resistance Screen; In vivo natural killer (NK) cell and CD8+ cytotoxic T lymphocyte (CTL) cytotoxicity screen). Blood analysis by flow cytometry was normal. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Nature of Mutation |
The madcow mutation was mapped by scoring the behavior of 27 F2 mice generated by outcrossing the madcow stock to mice of the C3H/HeN strain and backcrossing the F1 animals to mice of the madcow stock. The mutation was initially assigned to the proximal 25.72 Mb of chromosome 8 with a LOD score of 6.68 (Figure 3A). The identification and analysis of additional SNPs in the region allowed us confine the mutation to a critical region from 10.5 Mb to 13.06 Mb. All 15 protein-encoding exons and splice junctions in the region were sequenced using a semiautomated method described previously (1), to a greater than 98% coverage. A single mutation was found, corresponding to a T to A transversion at position 1007 of theCars2 transcript, in exon 9 of 15 total exons (Figure 3B). 992 ACAGAAGAAAAGATGTCCAAATCCCTAAAAAAC 300 -T--E--E--K--M--S--K--S--L--K--N- The mutated nucleotide is indicated in red lettering, and results in a serine to threonine change at amino acid 305 of the CARS2 protein. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Illustration of Mutations in Gene & Protein |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Protein Prediction | Cysteinyl-tRNA synthetase 2 (CARS2 or CysRS2) is a predicted mitochondrial-specific member of the class I aminoacyl-tRNA synthetase (ARS) protein family. Aminoacyl-tRNA synthetases catalyze the specific attachment of each of the 20 amino acids (aa) to a cognate transfer RNA (tRNA) (see Background). The ARSs are grouped into 16 cytoplasmic and 17 mitochondrial-specific enzymes with 3 enzymes functioning in both compartments. One ARS (glutamyl-prolyl-tRNA synthetase) attaches glutamic acid and proline to both tRNAglu and tRNApro, respectively. The nomenclature for human ARSs generally involves the use of the single-letter amino acid code followed by ‘ARS’ or ‘RS’. Mitochondrial-specific ARSs have a ’2’ added at the end (2). The ARSs are also often named by listing the first three letters of the amino acid catalyzed by the enzyme and ’RS’. ARSs are also subdivided into class I and class II enzymes based on the architectures of their active sites (Table 1). The catalytic domains of class I enzymes are characterized by a Rossmann dinucleotide binding fold consisting of a five-stranded parallel β-sheet connected by α-helices while class II enzymes have a core made up of a seven-stranded β-structure with flanking α-helices (3). Class I enzymes usually exist in monomeric or dimeric form, while class II ARSs are dimeric or tetrameric. Class I and II enzymes are further subdivided into subclasses (a, b, and c) based on sequence similarity, and amino acid chemical types. Subclass a includes synthetases for many of the hydrophobic amino acids, subclass b contains synthetases for carboxyl side-chain amino acids and amidated derivatives, and subclass c includes synthetases for aromatic amino acids (4). Although class I and class II enzymes do not appear to have any structural relationship, it has been postulated that the genes encoding both classes arose from a series of duplications from an ancestral gene where complementary strands of the gene coded for class I and II proteins. The conserved catalytic domains of the class I and II synthetases display complementarity that is specific to each subclass (a,b or c), and bind to opposite sides of the acceptor helix domains of tRNAs (5;6). Table 1. Categorization of aminoacyl tRNA synthetases
Besides their catalytic domains, aminoacyl-tRNA synthetases contain an anticodon binding domain, which mostly interacts with the anticodon region of the tRNA and ensures binding of the correct tRNA to the protein. In addition, some ARSs have additional RNA binding domains and editing domains that cleave incorrectly paired aminoacyl-tRNA molecules (2;4) (Figure 4). CARS2 is a member of subclass a and is predicted to be the synthetase used to attach cysteines to cognate tRNAs in the mitochondria (7). CARS2 contains a mitochondrial targeting sequence at its N-terminus. Mitochondrial targeting sequence have no real consensus, but are enriched in positively charged, hydrophobic and hydroxylated residues, and often have the potential to form amphipathic α-helices (8). Most mitochondrial ARSs are more similar to bacterial ARSs than to their cytoplasmic counterparts, which often contain additional domains (9;10). However, the few mitochondrial enzymes investigated have different biochemical and enzymological properties such as decreased solubility, decreased specific activity and ability to aminoacylate tRNAs of the same specificity from a large range of organisms, as compared to bacterial ARSs (10;11).
The crystal structure of E. coli CARS (PDB ID 1LI7 ; 1U0B ) reveals the typical catalytic Rossmann-fold of class I synthetases at the N-terminus, a small connective polypeptide insertion (the CP domain) that connects the two halves of the Rossmann fold, a stem-contact fold (the SC fold) that contacts the tRNA stem, a helical bundle domain conserved in all subclass 1a tRNA synthetases, and a unique mixed α/β anticodon-binding domain that provides the specificity determinants for all three anticodon nucleotides and beomes ordered upon tRNA binding (12;13) (Figure 5). Binding tRNA also orders residues in the CP domain to form a short helix-loop segment that may help orient the tRNA acceptor end into the active site (13). The CP domain is folded into a four-stranded antiparallel β-sheet motif common to all class Ia and b tRNA synthetase structures. Class I ARSs contain two conserved motifs that are critical for enzyme function. The HIGH motif (named for its component amino acids) is located within the first half of the Rossman fold and helps to correctly position the adenine base of ATP and provide interactions with the phosphates. The KMSKS motif is located on a flexible loop in the SC-fold domain directly following the final C-terminal β-strand of the Rossman fold. Binding ATP, positions this loop in a closed conformation in which the second lysine is positioned to stabilize the α-phosphate in the first transition state of aminoacylation (14-16). This motif also binds at the inside corner of the L-shaped tRNA molecule, and positions of the tRNA on the enzyme’s surface (17;18). The SC-fold domain consists of a β-α-α-β-α structure. The C-terminal helical domain is smaller than other class Ia ARSs and consists of four antiparallel α-helices. Cysteine binds at the base of the active site cleft in a position similar to the amino acid binding sites of other class I tRNA synthetases and makes interactions with amino acids in both the first and second halves of the Rossman fold. Five strictly conserved histidine residues are present at the base of the amino acid binding cleft (12). CARS does not have the editing domain found in many ARSs that is able to catalyze the hydrolysis of incorrectly attached amino acids (19), but the interaction of the cysteine thiol group with a tightly bound zinc molecule found at the base of the amino acid binding site provides binding specificity (12;20). Unlike bacterial CARS, eukaryotic CARS exists in dimeric form, although the significance of this is unknown (21;22). Human CARS contains extension domains as compared with its prokaryotic homologs: a 30 amino-acid N-terminal peptide, a 100 amino acid insertion domain in place of the CP domain located between the two halves of the Rossmann fold, and a 100 amino acid C-terminal extension. Only the C-terminal polypeptide is conserved among eukaryotic CARS proteins, and is used to selectively improve recognition and binding of the anticodon sequence (23).
Aminoacyl synthetases must be able to recognize specific tRNAs. Generally, tRNAs have a globular ‘hinge’ region located at the junction between two duplex helical arms that form an L shape (Figure 6). Bacterial CARS recognizes tRNAcys by elements in its globular core including the presence of some unusual properties specific to tRNAcyssuch as a G15-G48 pairing between the 3’-terminal nucleotide of the variable loop and a nucleotide of the D loop. Other unusual features of tRNAcys include a unique C-C pairing that stacks above the G-G pair and the base triples that stack below this pair (24). CARS recognizes tRNAcys by the presence of four nucleotides: the 5'-GCA-3' anticodon (25) and U73 in the acceptor stem (26;27), all of which are strictly conserved among tRNAcys species. U73 allows CARS to attach the cysteine to either the 2’ or 3’-hydroxyl group of the terminal ribose, unlike other class I ARSs that attach the amino acid substrate to the 2’-hydroxyl group (28). The mixed α/β C-terminal domain of CARS makes specific hydrogen bonding interactions with all three bases of the GCA anticodon (13). Other interactions include the a-helical bundle domain and the D and anticodon stems, which form the vertical arm of the L-shaped tRNA. The contacts in this region are almost exclusively with the sugar-phosphate backbone of the tRNA. tRNA recognition by human CARS differs from that of E. coli CARS in that human CARS does not depend on the nature of the 15–48 base pair as a selective determinant for aminoacylation (26). Mitochondrial (mt)-tRNAs are atypical with biased sequences, size variations in loops and stems, and absence of residues forming classical tertiary interactions, raising questions about how mt-ARSs specifically bind to mt-tRNAs (9;11). Some species of archaebacteria do not have a CARS enzyme, and are also missing enzymes that typically synthesize cysteine. Instead, cysteine is directly synthesized on tRNAcys using two enzymes, O-phosphoseryl-tRNA synthetase (SepRS) and O-phosphoseryl-tRNA:cysteinyl-tRNA synthase (SepCysS). During this process, SepRS aminoacylatestRNAcyswith O-phosphoserine, followed by conversion of the O-phosphoserine to cysteine by SepCysS (29). A similar reaction occurs in all species during the formation of selenocysteinyl-tRNAsec. Selenocysteine (Sec) is present in the active sites of enzymes in removing reactive oxidative species. tRNAsec is first misacylated by SARS to form Ser-tRNAsec, followed by phosphorylation of the serine by O-phosphoseryl-tRNA kinase (PSTK). The phosphoseryl (Sep) is then converted into Sec by Sep-tRNA:Sec-tRNA synthase (SepSecS) (29;30). In vitro, CARS is able to use Sec to aminoacylate tRNAcys. It is likely that the tRNAsec-dependent means of Sec synthesis restricts the formation of misacylated tRNAcys (29). The madcow mutation results in a conservative alteration of amino acid 305 from a serine to a threonine. KMSKS is considered necessary for CARS2 to engage ATP and position tRNA to allow aminoacylation (2), and the serine residue altered by the madcow mutation in this motif is thought to interact transiently with the pyrophosphaste moiety of ATP during the aminoacylation reaction (16). | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Expression/Localization | According to BioGPS, the gene is highly expressed in human in immune cells such NK cells, dendritic cells (DCs), B cells, T cells and monocytes. In mouse, it is expressed in many tissues but most highly in the heart. There are fairly high expression levels in erythrocyte, monocyte and myeloid precursors, liver, kidney and immune cells. Expression levels are low in the brain. Gene expression in the mouse kidney occurred at embryonic day (E)18.5 and in adults, but not at post natal day (P)1 (31). In situ hybridization studies found Cars2 mRNA to be at low levels in 8 week-old C57BL/6J male mouse cortex, hippocampal regions, and olfactory bulb (please see the Allen Brain Atlas). CARS2 is predicted to localize to the mitochondrion based on the presence of a mitochondrial targeting sequence (7). | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Background | Aminoacyl tRNA synthetases play a critical role in protein biosynthesis by covalently attaching amino acids to the appropriate transfer RNA (tRNA) in a process known as tRNA charging or activation. tRNAs have a site for amino acid attachment, and an anticodon site that is complementary to the mRNA triplet that codes for a specific amino acid. In a two-step reaction as shown below, ARSs join amino acids by their carboxyl group to the 3’-end of tRNAs to make an aminoacyl-tRNA molecule: 1. amino acid + ATP → aminoacyl-AMP + PPi 2. aminoacyl-AMP + tRNA → aminoacyl-tRNA + AMP Class I and II enzymes aminoacylate at the 2’ and 3’-hydroxyl group of an adenosine nucleotide, respectively, due to the structures of their active sites. The 2’-O-aminoacyl eventually migrates to the 3’ position via transesterification (28). Aminoacyl-tRNAs then travel inside the ribosome, where mRNA codons are matched through complementary base pairing to specific tRNA anticodons. The amino acids that the tRNAs carry are then used to assemble a protein. Termination of the polypeptide occurs at stop codons, which do not have cognate tRNAs. Instead, releasing factors recognize nonsense codons allowing the release of the polypeptide chain. The catalytic efficiency of ARSs is often enhanced by editing domains (see Protein Prediction), specialized N- or C-terminal tRNA binding domains that help dock tRNAs, and association with RNA-binding trans-acting factors or elongation factor subunits that facilitate tRNA trafficking (32). Some of the ARS proteins have a secondary functions ranging from transcriptional control to angiogenic signaling (2;32) (Table 2). ARSs can catalyze a secondary chemical reaction using ATP or ADP instead of tRNA to synthesize diadenosine oligophosphates (ApnA), which can act as signaling molecules (33), and some ARSs (DARS, EPRS, IARS, KARS, LARS, MARS, QARS, and RARS) interact in a multiple synthetase complex in eukaryotic cells. Three non-enzymatic proteins known as ARS-interacting multi-functional proteins (AIMPs) are also part of the complex. Although the exact roles of these complexes are unknown, they likely regulate both the canonical and secondary functions of tRNA synthetases (2;32). Table 2. ARS secondary functions
Many of the secondary functions attributed to ARSs involve the immune system. Both YARS and KARS are secreted in response to tumor necrosis factor (TNF)-α (34;35). The cleavage of YARS by leukocyte elastase results in an N-terminal fragment that is an interleukin-8-like cytokine and has proangiogenic activity, and a C-terminal fragment that becomes an immune cell stimulant for migration and production of tissue factor, myeloperoxidase, and additional TNF-α (36;37). KARS also regulates TNF-α production by activating MAP kinase pathways in macrophages and peripheral blood mononuclear cells (35). KARS is also involved in the packaging of HIV, and regulates mast cell transcription via production of Ap4A in the nucleus (33). HARS and NARS also stimulate immune cells by interacting with cell surface chemokine receptors (38). WARS undergoes alternative splicing that removes an N-terminal domain and generates active cytokines that inhibit the proangiogenic activities of YARS (39). In response to interferon (IFN)-γ signaling, EPRS silences translation of ceruloplasmin, a copper-binding plasma protein with important roles in inflammation and iron homeostasis (40). QARS can inhibit apoptosis in response to TNF-α and other stimuli (41). Disease-causing mutations in cytoplasmic ARS-encoding genes have been found in both humans and mice. In humans, Charcot-Marie-Tooth type neuropathies (dominant intermediate CMT, OMIM #608323; CMT2D, OMIM #601472), which cause peripheral neuronal degeneration, are caused by dominant mutations in YARS and GARS, respectively (2). Mutations in GARS can also cause distal hereditary motor neuronopathy type V (HMN5; #600794), while a heterozygous point mutation in mouse Gars results in severe neuromuscular dysfunction by three weeks of age and a shortened life span. The homozygous mutation is embryonic lethal. Interestingly, a null allele of Gars in the mouse is completely recessive, suggesting that the protein defect associated with the point mutation results in dominant-negative function (42). In drosophila melanogaster,a neuronal-specific Gars mutation causes defects in the formation of dendritic terminals and axonal arbors (43). In sticky mice, a mutation in Aars causes progressive cerebellar ataxia and rough, unkempt fur (44). Mutations in human CARS have not been identified, although a strong association for diabetic nephropathy was identified at this locus (45). Finally, the autoimmune diseases polymyositis and dermatomyositis are a consequence of autoantibodies directed against one or more ARSs with subsequent lymphocytic destruction of myocytes (46). Mitochondrial tRNA synthetases are nuclear-encoded and imported into the mitochondria where they fulfill the necessary function of charging mt-tRNAs. In humans and mice, only 13 proteins involved in oxidative phosphorylation are encoded by mitochondrial DNA (Table 3), but all of these are essential for mitochondrial function (47). Mitochondria are known as the power plant of the cell as they generate most of the cells supply of ATP. In addition to supplying cellular energy, mitochondria are involved in a range of other processes, such as signaling, cellular differentiation, cell death, as well as the control of the cell cycle and cell growth. Thus, complex protein-import machineries exist in mitochondria to ensure the correct import, membrane translocation and sorting of the 1000–1500 distinct mitochondrial proteins that are synthesized on cytosolic ribosomes (8). Although the mitochondrial genome encodes a full set of mt-tRNAs, import of cytoplasmic tRNAs can occur (48). Several disorders are associated with inherited mitochondrial defects that are caused by mutations in genes encoding mitochondrial-specific proteins or tRNAs (2;49). Mutations in mt-tRNAs usually result in the reduction of aminoacylation efficiency causing decreased mitochondrial protein synthesis and defects in oxidative phosphorylation. Muscle, liver and neurons are often affected in inherited mitochondrial disorders as they are highly metabolic and require large amounts of ATP production for proper cellular functioning. tRNA and mitochondrial protein-linked disorders cover a wide range of symptoms and syndromes such as myopathies, encephalopathies, cardiopathies, deafness, ophthalmoplegia, and diabetes (49). These disorders include Myoclonic Epilepsy and Red Ragged Fibers (MERFF; OMIM #540000), the progressive neurodegenerative disorder known as Leigh syndrome (OMIM #256000), MELAS syndrome (mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes; OMIM #540000), and Leber optic atrophy (OMIM #535000) (50). The differences in clinical phenotypes in patients with these mt-tRNA mutations reflects the often heteroplasmic nature of these diseases and the metabolic needs of different tissues. Mutations in mt-tRNAcys cause encephalopathy and/or myopathy(51;52). Similar phenotypes can also be caused by mutations in mt-ARSs. Mutations in human RARS2 cause a form of pontocerebellar hypoplasia (PCH6; OMIM #611523), associated with reduced levels of charged mt-tRNAarg and mitochondrial respiratory chain defects (53). In yeast, ARS deficiencies cause respiration defects (54). However, defects in mt-ARSs do not necessarily mimic mutations in the cognate tRNA. Mutations in human DARS2 results in leukoencephalopathy with brain stem and spinal cord involvement and lactate elevation (LBSL; OMIM #611105) (55), while mutations in mt-tRNAasp cause myopathy (56). Although the enzyme activities of DARS2 proteins from human patients were decreased, mitochondrial functions appeared to be normal (55). | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Putative Mechanism |
As the madcow mutation results in an amino acid change in a motif important for catalytic function of CARS2, the extent of aminoacylation and the stability of the mitochondrial tRNAcys transcript was tested in various tissues from homozygous madcow and control males and females of young (6-8 weeks) and old (18 months) age groups using quantitative Northern blot hybridization and measuring the amount of the aminoacylated tRNA relative to total tRNA (Figure 7). Although aminoacylation was not detectable in the brains or livers of any of the mice, aminoacylation was clearly observed in the heart and skeletal muscle of wild type mice with activity decreasing with age in the heart. In these tissues the catalytic function of CARS2 was found to be reduced in mutant animals. These data experimentally prove that CARS2 can aminoacylate mitochondrial tRNAcys.
As CARS2 is predicted to be necessary for mitochondrial protein synthesis, mitochondrial function may be compromised in madcow mice, particularly in the heart where diminished steady-state tRNAcys aminoacylation was observed. Histological analysis of heart tissue from 9 month old female madcow mice disclosed no abnormalities either by light microscopy or electron microscopy (Figure 8A). Using quantitative PCR to compare the amount of mitochondrial DNA to the amount of nuclear DNA (57), madcow mice appear to have a normal number of mitochondrial genomes in the spleen, muscle and brain (Figure 8b). Mitochondria from the brains and hearts of madcow and control animals were then isolated and functionally assessed examining oxygen consumption rates and activities of the four mitochondrial complexes involved in respiration. Oxygen consumption rates and mitochondrial complex activity were normal in madcow mitochondria (Figure 9A,B).
Finally, mitochondrially-synthesized proteins were examined by Western blot. 11 of the 13 protein encoded by the mitochondrial genome contain cysteines (Table 3), but all proteins tested were expressed normally in madcow animals (Figure 9C). Madcow and wild type mice were subjected to several stress tests including prolonged treadmill running and low temperatures. Madcow mice performed normally when subjected to prolonged and intensive exercise on a treadmill, and were able to maintain normal body temperatures when placed at 13oC for 7 days (57). These results further indicate normal mitochondrial function in madcow mice. Table 3. Mitochondrial protein cysteine content and deficiency phenotypes
Despite the finding of diminished mitochondrial tRNAcys aminoacylation in heart and skeletal muscle, homozygous madcow animals fail to display any defects in mitochondrial morphology or function. These animals also appear to synthesize normal amounts of cysteine-containing mitochondrial proteins, and show a normal capacity for prolonged exercise and adaptation to low temperature. However, mutations in mitochondrial aminoacyl-tRNA synthetases do not necessarily cause overt mitochondrial dysfunction, as manifested by inadequate electron transport or limitations in energy transduction. Similar to the observations of mitochondrial function in madcow mice, humans with a mutation in DARS2 display reduced enzymatic activity but no defects in mitochondrial function. Like madcow mice, these patients display neurological defects, albeit distinct from those characteristic of madcow, including progressive cerebellar ataxia, spasticity and dorsal column dysfunction, sometimes with a mild cognitive deficit or decline (55). The basis for the neurobehavioral defects observed in madcow mice remains to be determined. Madcow animals display normal brain morphology and mitochondrial function, as well as hearing. However, the brain is highly sensitive to defects in mitochondrial function, and most disease-causing mutations found in genes encoding both cytoplasmic and mitochondrial ARSs are associated with neurological phenotypes. In many of these cases, the affected ARS proteins are not expressed preferentially in the brain (2). As a generalization, the tissue-specific effects of a hypomorphic mutation reflect: 1) the degree to which the mutated protein exists in excess of requirement within a given tissue; and 2) the degree to which the mutation diminishes activity or functionality of the affected protein within that tissue. In the experiments shown above, the steady state tRNAcys aminoacylation was beneath the level of detection in brain (as in liver). It is possible that even relatively modest impairment of CARS2 catalytic activity, caused by the S305T mutation within a restricted subset of neurons or glial cells, might compromise mitochondrial protein synthesis so as to cause the observed neurobehavioral phenotype. By contrast, tRNAcys aminoacylation in the heart, while beneath detection at steady state in madcow animals, likely occurs at a pace sufficient to sustain adequate mitochondrial protein synthesis in cardiomyocytes. In skeletal muscle, the effect of the mutation is comparatively modest, in that only a 25% to 50% decrement in the steady state level of aminoacylated tRNAcys is observed. While the residue in the critical ATP-binding motif of CARS2 altered by the madcow mutation is invariably a serine in all eukaryotic tRNA synthetases, some bacterial species display other amino acids, including threonines, at this position in some tRNA synthetase sequences (58). Targeted mutagenesisof the residues in the KMSKS motif of tyrosyl-tRNA synthetase suggests that nonconservative mutations of the first serine only mildly affect enzyme activity (16), and that replacement of this residue with a threonine does not affect enzyme activity in bacteria(58). Thus, the serine to threonine change in the madcow CARS2 protein likely permits partial retention of enzymatic activity. Temporal progression of the madcow phenotype may result from accumulation of mitochondrial mutations with increasing age (49). This hypothesis assumes that diminished mitochondrial function caused by the madcow mutation, however slight, becomes functionally significant as mitochondria are damaged by mutation. Alternatively, temporal progression may result from diminished Cars2 expression in specific cells of the CNS, occurring with age. The appearance of the madcow phenotype at an earlier age in female mice may suggest sexual dimorphism in gene expression at the Cars2 locus, and is likely to be hormone-dependent. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Primers | Primers cannot be located by automatic search. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Genotyping | Madcow genotyping is performed by amplifying the region containing the mutation using PCR, followed by sequencing of the amplified region to detect the single nucleotide change. Primers for PCR amplification Mad(F): 5’- GCTGTGTGGACCTGTTATTGTACCCTCACTG -3’ Mad(R): 5’- GCCCCTTGAAACAAGAAGGAGCAATTCCCTG -3’ PCR program 1) 94°C 2:00 2) 94°C 0:30 3) 56°C 0:30 4) 72°C 1:00 5) repeat steps (2-4) 29X 6) 72°C 7:00 7) 4°C ∞ Primers for sequencing Mad_seq(F): 5’- TATTGTCCTGGAAGAGCACAC -3’ Mad_seq(R): 5’- GGCTAGGTCAGACTACATGTC -3’ The following sequence of 481 nucleotides (from Genbank genomic region NC_000074 for linear DNA sequence of Cars2) is amplified: 29358 gct gtgtggacct gttattgtac cctcactgag cagtattgtc 29401 ctggaagagc acacactgca ggtgcaggtt cctgtcctgt atcctgtggg gaaacacagg 29461 cctgtggcta cactggccca gctgtgtcta gctaggctca gggctataga cagagaagct 29521 gaactccctt ctggtgccct ggtaactgtg catgggtggg gcgggctcag ggctgcctaa 29581 aagagcctgt acctggagtg gatatttctc tttttgtttc aggtcatttg catgtgaaag 29641 gcacagaaga aaagatgtcc aaatccctaa aaaactatat caccattaag gtaacgtcaa 29701 tagacagtgc cttcctgcgt gagtggctga tggctgctag gggcctctgt agggtgaaat 29761 cacatcacta gacatgtagt ctgacctagc cctgcatggg ctgcctccag ggaattgctc 29821 cttcttgttt caaggggc PCR primer binding sites are underlined; sequencing primer binding sites are highlighted in gray; the mutated T is shown in red text. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
References |
45. Pezzolesi, M. G., Poznik, G. D., Mychaleckyj, J. C., Paterson, A. D., Barati, M. T., Klein, J. B., Ng, D. P., Placha, G., Canani, L. H., Bochenski, J., Waggott, D., Merchant, M. L., Krolewski, B., Mirea, L., Wanic, K., Katavetin, P., Kure, M., Wolkow, P., Dunn, J. S., Smiles, A., Walker, W. H., Boright, A. P., Bull, S. B., DCCT/EDIC Research Group, Doria, A., Rogus, J. J., Rich, S. S., Warram, J. H., and Krolewski, A. S. (2009) Genome-Wide Association Scan for Diabetic Nephropathy Susceptibility Genes in Type 1 Diabetes. Diabetes. 58, 1403-1410. 46. Park, S. G., Schimmel, P., and Kim, S. (2008) Aminoacyl tRNA Synthetases and their Connections to Disease. Proc. Natl. Acad. Sci. U. S. A.. 105, 11043-11049. 47. Schaefer, A. M., Taylor, R. W., and Turnbull, D. M. (2001) The Mitochondrial Genome and Mitochondrial Muscle Disorders. Curr. Opin. Pharmacol.. 1, 288-293.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Science Writers | Nora G. Smart | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Illustrators | Diantha La Vine | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Authors | Celine Eidenschenk, Xin Du, Yee Ting Chong, Weiwei Fan, Bethany Frazen, Heather Elledge, Anastasia Kralli, Ronald M. Evans, Ulrich Mueller, Paul Schimmel, Xiang-Lei Yang, and Bruce Beutler |